Rome, Italy

Nicola Pescosolido

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 2.3

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2010-2013

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Nicola Pescosolido: Innovator in Ophthalmic Drug Delivery

Introduction

Nicola Pescosolido is a prominent inventor based in Rome, Italy. He has made significant contributions to the field of ophthalmology through his innovative inventions. With a total of 4 patents, Pescosolido has focused on developing advanced solutions for the delivery of ophthalmic drugs.

Latest Patents

One of his latest patents is a gel useful for the delivery of ophthalmic drugs. This invention relates to a solid powder composed of a mixture of a natural or synthetic polymer that forms a gel, a buffer such as a hydroxyacid or a dicarboxyacid, a saccharide, and one or more drugs useful for treating eye diseases. Additionally, it may include one or more excipients and/or regulators of osmotic pressure that are ophthalmologically acceptable. Another notable patent involves the use of L-carnitine or alkanoyl L-carnitines for preparing a physiological supplement or medicament for ophthalmic use in the form of eye drops. This invention aims to treat corneal diseases effectively.

Career Highlights

Nicola Pescosolido works at Sigma-Tau Industrie Farmaceutiche Riunite S.p.a., where he continues to innovate in the pharmaceutical industry. His work has been instrumental in advancing treatments for various ocular conditions.

Collaborations

Some of his notable coworkers include Aleardo Koverech and Antonio Longo, who have collaborated with him on various projects within the field.

Conclusion

Nicola Pescosolido's contributions to ophthalmic drug delivery highlight his commitment to improving patient care through innovation. His patents reflect a deep understanding of the complexities involved in treating eye diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…